Skip to main content

NOTICE: Due to a lapse in annual appropriations, most of this website is not being updated. Learn more.

Form submissions will still be accepted but will not receive responses at this time. Sections of this site for programs using non-appropriated funds (such as NVLAP) or those that are excepted from the shutdown (such as CHIPS and NVD) will continue to be updated.

U.S. flag

An official website of the United States government

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you’ve safely connected to the .gov website. Share sensitive information only on official, secure websites.

Proflavine Acts as a Rev Inhibitor by Targeting the High-Affinity Rev Binding Site of the Rev-Responsive Element of HIV-1

Published

Author(s)

E S. DeJong, C Chang, M K. Gilson, John Marino

Abstract

Rev is an essential regulatory HIV-1 protein that binds the Rev Responsive Element (RRE) within the env gene of the HIV-1 RNA genome, activating the switch between viral latency and active viral replication. Previously, we have shown that selective incorporation of the fluorescent probe, 2-aminopurine (2-AP), into a truncated form of the RRE sequence (RRE-IIB) allowed the binding of an arginine-rich peptide derived from Rev and aminoglycosides to be characterized directly by fluorescence methods. Using these fluorescence as well as nuclear magnetic resonance (NMR) methods, proflavine has been identified, through a limited screen of selected small heterocyclic compounds, as a specific and high-affinity RRE-IIB binder which inhibits the interaction of Rev peptide with RRE-IIB. Direct and competitive 2-AP fluorescence binding assays reveal that there are at least two classes of proflavine binding sites on RRE-IIB: a high-affinity site that competes with Rev peptide for binding to RRE-IIB (KD 0.1 0.05 mM) and a weaker binding site(s) (KD 1.1 0.05 mM). Titrations of RRE-IIB with proflavine, monitored using 1H NMR, demonstrate that proflavine binds with a 2:1 [proflavine:RRE-IIB] stoichiometry and NOEs observed in the NOESY spectrum of the 2:1 proflavineoRRE-IIB complex indicate that the two proflavine molecules bind specifically and in close proximity to each other within a single binding site. NOESY data further indicate that formation of the 2:1 proflavineoRRE-IIB complex stabilizes base pairing and stacking within the internal purine-rich bulge of RRE-IIB in a manner analogous to what has been observed in the Rev peptideoRRE-IIB complex. The observation that proflavine competes with Rev for binding to RRE-IIB by binding as a dimer to a single high-affinity site opens the possibility for rational drug design based on linking and modifying it and related compounds.
Citation
Biochemistry
Volume
42
Issue
No. 26

Keywords

2-aminopurine, fluorescence, HIV-1, NMR, Proflavine, RRE, structure

Citation

DeJong, E. , Chang, C. , Gilson, M. and Marino, J. (2003), Proflavine Acts as a Rev Inhibitor by Targeting the High-Affinity Rev Binding Site of the Rev-Responsive Element of HIV-1, Biochemistry (Accessed October 10, 2025)

Issues

If you have any questions about this publication or are having problems accessing it, please contact [email protected].

Created July 7, 2003, Updated October 12, 2021
Was this page helpful?